Literature DB >> 6245793

Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil.

B Ardalan, D A Cooney, H N Jayaram, C K Carrico, R I Glazer, J Macdonald, P S Schein.   

Abstract

The biochemical basis for the resistance of murine leukemia P388 to 5-fluorouracil (FUra) was systematically investigated by examining the transport and metabolism of FUra, or its anabolites, as well as the inhibition of enzymes and processes known to be affected by the drug. Of these parameters, only three were found to be altered significantly in the resistant line: (a) the enzyme required for the phosphorylation of uridine 5'-monophosphate to uridine 5'-diphosphate was present at a significantly lower specific activity in the resistant line than in its sensitive counterpart; (b) the rates of generation and persistance of 5-fluoro-2'-deoxyuridine 5'-monophosphate were significantly lower and shorter in the variant; and (c) there was a 1.6- and 3-fold decrease in the incorporation of FUra into polyadenylic acid-containing RNA and polyadenylic acid-lacking RNA, respectively, in resistant versus sensitive cells. Taken together, these findings suggest a dual mechanism for resistance to FUra in these leukemic cells, namely, a depressed capacity to generate di- and triphosphates of the riboside and deoxyriboside of the drug leading to lower pools of the proximate antimetabolite, fluorouridine 5'-triphosphate, and accelerated excretion of 5-fluoro-2'-deoxyuridine 5'-monophosphate, so that thymidylate synthetase is perturbed in a less than lethal way.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245793

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

3.  Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.

Authors:  M Iigo; M Miwa; H Ishitsuka; K Nitta
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.

Authors:  M Iigo; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil.

Authors:  Ziyaur Rahman; Kanchan Kohli; Shuang-Qing Zhang; Roop K Khar; Mushir Ali; Naseem A Charoo; Mohammad Tauseef; Areeg A A Shamsher; Noorullah N Mohammed; Michael A Repka
Journal:  J Pharm Pharmacol       Date:  2008-05       Impact factor: 3.765

7.  Incorporation of intermediary products of 5-FU anabolism into colorectal cancer.

Authors:  G R Giles; L Woodhouse; P J Finan; E M Chisholm
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

8.  5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil.

Authors:  Shigehiro Tsujimoto; Kiyohide Fujimoto; Eijiro Okajima; Seiichiro Ozono; Eigoro Okajima; Yoshihiko Hirao
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

9.  Kinetic analysis of 5-fluorouracil action against various cancer cells.

Authors:  M Inaba; J Mitsuhashi; S Ozawa
Journal:  Jpn J Cancer Res       Date:  1990-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.